Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer

Marta Venturelli,1 Giorgia Guaitoli,1 Claudia Omarini,1 Luca Moscetti2 1Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Modena, Italy; 2Division of Medical Oncology, Department of Oncology and Hematology, Azienda...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Venturelli M, Guaitoli G, Omarini C, Moscetti L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	adjuvant hormone therapy LHRH amenorrhea Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8bcef3965a734bd6869312ece9f710af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8bcef3965a734bd6869312ece9f710af
record_format	dspace
spelling	oai:doaj.org-article:8bcef3965a734bd6869312ece9f710af2021-12-02T01:17:57ZSpotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer1179-1314https://doaj.org/article/8bcef3965a734bd6869312ece9f710af2018-03-01T00:00:00Zhttps://www.dovepress.com/spotlight-on-triptorelin-in-the-treatment-of-premenopausal-women-with--peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Marta Venturelli,1 Giorgia Guaitoli,1 Claudia Omarini,1 Luca Moscetti2 1Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Modena, Italy; 2Division of Medical Oncology, Department of Oncology and Hematology, Azienda Ospedaliero Universitaria Policlinico di Modena, Modena, Italy Abstract: Endocrine treatment represents the cornerstone of endocrine-sensitive premenopausal early breast cancer. The estrogen blockade plays a leading role in the therapeutic management of hormone receptor-positive breast cancer together with surgery, radiotherapy, and selective antiestrogen treatments. For several years, selective estrogen receptor modulators, such as tamoxifen, have represented the mainstay of therapy. The role of amenorrhea has been extensively elucidated in the past year: the benefit observed with chemotherapy-induced amenorrhea has strengthened its therapeutic role. Luteinizing hormone-releasing hormone (LHRH) has been introduced in oncology practice to induce amenorrhea in order to increase the advantage obtained from endocrine treatment. Triptorelin is one of the most widely used LHRH analogs currently available in clinical practice. It was recently investigated in two major clinical trials that studied the role of complete estrogen blockade in the premenopausal setting. Both showed the clinical benefit due to ovarian suppression treatment, primarily in high-risk patients. Furthermore, triptorelin and other LHRH analogs have recently been investigated in the attempt to preserve the ovarian function in young patients. The medical treatment of early breast cancer is always evolving in the effort to search for safe and efficacious treatments. The role of LHRH analogs is actually well recognized as contributing to the improvement of the medical treatment of premenopausal women with early breast cancer. Keywords: adjuvant, hormone therapy, LHRH, amenorrheaVenturelli MGuaitoli GOmarini CMoscetti LDove Medical Pressarticleadjuvanthormone therapyLHRHamenorrheaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 10, Pp 39-49 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	adjuvant hormone therapy LHRH amenorrhea Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	adjuvant hormone therapy LHRH amenorrhea Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Venturelli M Guaitoli G Omarini C Moscetti L Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
description	Marta Venturelli,1 Giorgia Guaitoli,1 Claudia Omarini,1 Luca Moscetti2 1Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Modena, Italy; 2Division of Medical Oncology, Department of Oncology and Hematology, Azienda Ospedaliero Universitaria Policlinico di Modena, Modena, Italy Abstract: Endocrine treatment represents the cornerstone of endocrine-sensitive premenopausal early breast cancer. The estrogen blockade plays a leading role in the therapeutic management of hormone receptor-positive breast cancer together with surgery, radiotherapy, and selective antiestrogen treatments. For several years, selective estrogen receptor modulators, such as tamoxifen, have represented the mainstay of therapy. The role of amenorrhea has been extensively elucidated in the past year: the benefit observed with chemotherapy-induced amenorrhea has strengthened its therapeutic role. Luteinizing hormone-releasing hormone (LHRH) has been introduced in oncology practice to induce amenorrhea in order to increase the advantage obtained from endocrine treatment. Triptorelin is one of the most widely used LHRH analogs currently available in clinical practice. It was recently investigated in two major clinical trials that studied the role of complete estrogen blockade in the premenopausal setting. Both showed the clinical benefit due to ovarian suppression treatment, primarily in high-risk patients. Furthermore, triptorelin and other LHRH analogs have recently been investigated in the attempt to preserve the ovarian function in young patients. The medical treatment of early breast cancer is always evolving in the effort to search for safe and efficacious treatments. The role of LHRH analogs is actually well recognized as contributing to the improvement of the medical treatment of premenopausal women with early breast cancer. Keywords: adjuvant, hormone therapy, LHRH, amenorrhea
format	article
author	Venturelli M Guaitoli G Omarini C Moscetti L
author_facet	Venturelli M Guaitoli G Omarini C Moscetti L
author_sort	Venturelli M
title	Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
title_short	Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
title_full	Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
title_fullStr	Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
title_full_unstemmed	Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
title_sort	spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/8bcef3965a734bd6869312ece9f710af
work_keys_str_mv	AT venturellim spotlightontriptorelininthetreatmentofpremenopausalwomenwithearlystagebreastcancer AT guaitolig spotlightontriptorelininthetreatmentofpremenopausalwomenwithearlystagebreastcancer AT omarinic spotlightontriptorelininthetreatmentofpremenopausalwomenwithearlystagebreastcancer AT moscettil spotlightontriptorelininthetreatmentofpremenopausalwomenwithearlystagebreastcancer
_version_	1718403149088161792

Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer

Ejemplares similares